# Memory

## Escalation Log

<!-- Log every model escalation here -->
<!-- Format: [DATE] Task: X | From: ollama/qwen → To: kimi-k2.5 | Reason: Y | Resolved: yes/no -->

## Key Learnings

<!-- Add learnings as you work -->

**[2026-03-18] Orchestration Role Learning — F6 Failure Logged**

### Critical Architecture Understanding

I violated my role as **Orchestrator** by executing work directly instead of delegating to subagents (Donna). This is an F6 coordination error.

**My Role (Shizzle):**
- Plan tasks and define frameworks
- Spawn subagents for execution
- Validate and review outputs
- Coordinate parallel work
- **NOT** execute content writing, coding, or other worker tasks

**Donna's Role (Subagent):**
- Execute content writing
- Perform research compilation
- Write code for website builds
- Run parallel tasks while I orchestrate
- **NOT** a smarter model — same capabilities, but enables parallelism

### Correct Workflow

For Phase 3 (Website Build):
- **I will:** Plan architecture, define requirements, set technical direction
- **Donna will:** Write actual Next.js code, implement features
- **I will:** Review, validate, test, deploy

### Key Realization

- Delegation improves quality (validation layer)
- Parallel execution speeds delivery
- Architecture matters — I must follow it
- Subagent spawning is not optional optimization — it's required design

### Prevention

- Read skill docs before new phases
- Spawn subagent for content generation
- Maintain orchestrator role (plan → delegate → validate)
- Update Archon status at phase transitions

---

**[2026-03-18] Phase 2 — Brand Strategy Complete**

### Brand Decisions
- **Tagline:** "Engineering Systems for Human Mobility" — balances technical credibility with aspirational mission
- **Positioning:** Nimble R&D partner to large incumbents, not competitor — avoids direct competition with Zimmer/Stryker scale
- **Cross-domain insight** is the core differentiator — no competitor covers implants + prosthetics + augmentation

### Messaging Framework
- **4 Pillars:** (1) Engineering Rigor, (2) Cross-Domain Insight, (3) Early-Stage Partnership, (4) Responsible Innovation
- **Tone:** Technical but accessible, credible not hype-driven, forward-looking but grounded
- **Compliance:** All messaging validated against AGENTS.md constraints (no FDA claims, no clinical outcomes)

### Platform Strategy
- **X:** Concise technical insights, industry conversation engagement
- **Instagram:** Visual storytelling, behind-the-scenes prototyping
- **LinkedIn:** Thought leadership, B2B positioning, professional credibility

**[2026-03-18] Phase 1 — Market Research Complete**

### Tools & Execution
- Web search hit rate limits on Gemini API after 1-2 queries; need to batch searches or use alternative methods
- Web fetch worked well for competitor website extraction
- Direct competitor research via fetch is more reliable than search for structured data gathering

### Domain Insights
- Orthopedic implant market dominated by 3-4 major players (Zimmer Biomet, Stryker, Smith+Nephew, DePuy Synthes)
- Prosthetics R&D landscape more fragmented with strong innovation from Össur, Ottobock, and specialized firms
- Exoskeleton space emerging with Ekso Bionics as FDA-cleared leader; Medicare coverage established in 2024
- Cross-domain positioning (implants + prosthetics + augmentation) is unique — no direct competitor covers all three

### Messaging Constraints Validated
- All major competitors use careful regulatory language
- "R&D," "prototyping," "concept design" are standard industry terms
- FDA approval claims are strictly regulated; our conservative approach is correct
- Defense R&D references require "conceptual work aligned with..." framing

### Strategy Implications
- Position as nimble R&D partner to large incumbents, not competitor
- Emphasize systems-level thinking across domains
- Las Vegas location requires remote collaboration emphasis
- Content strategy: technical credibility first, systems thinking second

## Domain Knowledge

<!-- Add biomedical engineering insights discovered during research -->

**Orthopedic Implants**
- Key innovation areas: wear surfaces, implant longevity, biomechanical alignment, materials optimization
- Major technologies: ROSA robotics (Zimmer Biomet), NAVIO (Smith+Nephew), MAKO (Stryker)
- Smart implants emerging: Persona IQ with sensor technology
- Materials focus: Titanium alloys, ceramics, polyethylene improvements

**Prosthetics**
- Bionic technology: Brain-controlled limbs, AI/robotics integration
- Microprocessor-controlled knees: C-Leg, Orion3, Power Knee
- Upper limb advances: i-Limb, bebionic hand, LUKE Arm
- Materials: Carbon-fiber composites (Flex-Foot), advanced polymers
- Research areas: Human-machine interfaces, quantum sensors for mind control

**Exoskeletons**
- FDA clearance path established: EksoNR cleared for stroke, brain injury, MS, SCI
- Medicare coverage: CMS established payment level for personal exoskeletons (2024)
- Target conditions: Spinal cord injury (T3-L5), stroke rehabilitation, MS
- Key metric: 500+ rehabilitation centers using Ekso technology globally
- Lightest system: Ekso Indego Personal (modular design)

**Regulatory Context**
- 510(k) pathway common for orthopedic devices
- Personal exoskeletons now in "brace" benefit category for Medicare
- FDA strictly regulates any clinical outcome claims
- CE marking required for European market access
